An above-average positive development in bioplastics production capacity has made past projections obsolete, according to a current market forecast, which the industry association European Bioplastics publishes annually in cooperation with the Institute for Bioplastics and Biocomposites from the University of Hannover.
The market of about 1.2 million tons in 2011 will see a fivefold increase in production volumes by 2016 – to an anticipated almost 6 million tons.
The worldwide production capacity for bioplastics will increase from around 1.2 million tons in 2011 to approximately 5.8 million tons by 2016.
By far the strongest growth will be in the biobased, non-biodegradable bioplastics group.
Especially the so-called “drop-in” solutions, such as bio-ppbased versions of bulk plastics like PE and PET, that merely differ from their conventional counterparts in terms of their renewable raw material base, are building up large capacities.
Leading the field is partially biobased PET, which is already accounting for approximately 40% of the global bioplastics production capacity.
Partially biobased PET will continue to extend this lead to more than 4.6 million tons by 2016.
That would correspond to 80% of the total bioplastics production capacity.
Following PET is bio-based PE with 250,000 tons, constituting more than 4% of the total production capacity.
“But also biodegradable plastics are demonstrating impressive growth rates. Their production capacity will increase by two-thirds by 2016,”states Hasso von Pogrell, MD of European Bioplastics.
Leading contributors to this growth will be PLA and PHA, each of them accounting for 298,000 tons (+50%) and 142,000 tons (+550%) respectively.
“The enormous growth makes allowance for the constantly increasing demand for sustainable solutions in the plastics market. Eventually, bioplastics have achieved an established position in numerous application areas, from the packaging market to the electronics sector and the automotive industry.”
A disturbing trend to be observed is the geographic distribution of production capacities.
Europe and North America remain interesting as locations for research and development and also important as sales markets.
However, establishment of new production capacities is favoured in South America and Asia.
“European Bioplastics invites European policy makers to convert their declared interest into concrete measures. We are seeing many general supportive statements at EU level and in the Member States”, says Andy Sweetman, chairman.
“There is, however, a lack of concrete measures. If Europe wants to profit from growth at all levels of the value chain in our industry, it is high time the corresponding decisions are made.”
